Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3
Year: 2023
Type: article
Abstract: 7. Health Canada.LIBTAYO ® -Notice of compliance with conditions -qualifying notice
Authors: Michael Migden, Chrysalyne Schmults, Nikhil Khushalani, Alexander Guminski, Anne Lynn Chang, Karl Lewis, George Ansstas, Samantha Bowyer, Brett Hughes, Dirk Schadendorf, Badri Modi, Lara Dunn, Lukas Flatz, Axel Hauschild, Suk-Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy, Matthew Fury, Danny Rischin
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funders: Sanofi, Regeneron Pharmaceuticals
OpenAlex ID: W4324057654